Dupilumab in papuloerythroderma of Ofuji: therapeutic efficacy and paradoxical flares in a case-based review

Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia et al. in 2009. This study aims to summarize the clinical manifestations, emerging treatments, and prognosis of PEO, and to explore the...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment Vol. 36; no. 1; p. 2562300
Main Authors: Liu, Teng, Zhang, Meixi, Gao, Xiaoman, Yang, Kun, Bao, Yingqiu, Zhang, Qiuli, Chang, Jianmin
Format: Journal Article
Language:English
Published: England Taylor & Francis Group 01.12.2025
Subjects:
Aged
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Dermatitis, Exfoliative - diagnosis
Dermatitis, Exfoliative - drug therapy
Dermatologic Agents - administration & dosage
Dermatologic Agents - adverse effects
Dermatologic Agents - therapeutic use
dupilumab
Female
Humans
Male
Middle Aged
Papuloerythroderma of Ofuji
Symptom Flare Up
treatment
Treatment Outcome
tripterygium glycosides
treatment
tripterygium glycosides
Papuloerythroderma of Ofuji
dupilumab
ISSN:0954-6634, 1471-1753, 1471-1753
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia et al. in 2009. This study aims to summarize the clinical manifestations, emerging treatments, and prognosis of PEO, and to explore the efficacy and paradoxical flares associated with dupilumab treatment. We report two cases associated with dupilumab treatment and conducted a search of PubMed, Embase, the China Knowledge Resource Integrated, and the Wanfang databases using the keywords 'papuloerythroderma of Ofuji' for the period from July 2009 to October 2024. A total of 52 patients were included, with onset most commonly occurring in their 70s. The systemic treatments included dupilumab (  = 7), cyclosporine (  = 6), oral glucocorticoids (  = 5), acitretin (  = 4), methotrexate (  = 3), and apremilast (  = 1). Dupilumab was administered to seven patients, and the skin lesions improved within a short period. No adverse effects were reported in three patients, although elevated eosinophil counts accompanied by worsening lesions were observed in one patient. Our findings suggest that dupilumab is the most commonly utilized treatment for PEO; however, elevated eosinophil counts and potential exacerbation of clinical symptoms warrant attention. Additionally, Tripterygium glycosides may be an effective therapy to improve these conditions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Review-5
content type line 23
ObjectType-Case Study-4
ObjectType-Feature-2
ObjectType-Report-3
ISSN:0954-6634
1471-1753
1471-1753
DOI:10.1080/09546634.2025.2562300